Precipitated withdrawal by pentazocine in methadone-maintained volunteers
- PMID: 7504098
Precipitated withdrawal by pentazocine in methadone-maintained volunteers
Abstract
Pentazocine is a partial mu agonist opioid with one-half to one-sixth the parenteral analgesic potency of morphine. The purpose of this study was to characterize the effects of pentazocine in comparison to naloxone (an opioid antagonist), hydromorphone (an opioid mu agonist) and saline in methadone-dependent volunteers by using the same experimental methods used previously in the study of the opioid analgesics buprenorphine, butorphanol and nalbuphine. In a residential laboratory, five volunteer male opioid abusers, maintained on 30 mg p.o. of methadone daily, underwent pharmacological challenges 2 to 3 times per week. Pharmacological challenges consisted of a double-blind i.m. injection of: pentazocine (dose range 7.5-120 mg), hydromorphone (5 and 10 mg), naloxone (0.1 and 0.2 mg) or saline. Injections were given 20 hr after the last dose of methadone. Measures included physiological indices and self-reports and observer ratings of drug effects. Naloxone and hydromorphone produced characteristic antagonist-like and agonist-like effects, respectively, on subjective, observer and physiological indices. Pentazocine produced primarily antagonist-like effects, with higher doses (> = 60 mg) producing significant elevations of visual analog scale ratings of Drug Effects, Bad Effects and Sick; of observer ratings of piloerection, restlessness and adjective scores of opioid withdrawal; as well as increases in blood pressure, heart rate and pupil diameter and decreases in skin temperature. Similar to the previous study of butorphanol, the specific profile of effects produced by pentazocine differed from that produced by naloxone, suggesting non-mu effects may modulate the mu effects of pentazocine.
Similar articles
-
Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.J Pharmacol Exp Ther. 1992 Jun;261(3):985-93. J Pharmacol Exp Ther. 1992. PMID: 1376362 Clinical Trial.
-
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.J Pharmacol Exp Ther. 1995 Feb;272(2):628-38. J Pharmacol Exp Ther. 1995. PMID: 7853176
-
Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.J Pharmacol Exp Ther. 1994 Mar;268(3):1485-92. J Pharmacol Exp Ther. 1994. PMID: 8138958 Clinical Trial.
-
Assessment of buprenorphine in a drug discrimination procedure in humans.NIDA Res Monogr. 1992;121:28-37. NIDA Res Monogr. 1992. PMID: 1406908 Review.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
Cited by
-
Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.J Pain. 2009 Oct;10(10):1038-50. doi: 10.1016/j.jpain.2009.03.017. Epub 2009 Sep 2. J Pain. 2009. PMID: 19729346 Free PMC article. Clinical Trial.
-
Treatment of opioid-dependent pregnant women: clinical and research issues.J Subst Abuse Treat. 2008 Oct;35(3):245-59. doi: 10.1016/j.jsat.2007.10.007. Epub 2008 Jan 14. J Subst Abuse Treat. 2008. PMID: 18248941 Free PMC article. Review.
-
Effects of buprenorphine and methadone in methadone-maintained subjects.Psychopharmacology (Berl). 1995 Jun;119(3):268-76. doi: 10.1007/BF02246290. Psychopharmacology (Berl). 1995. PMID: 7675960 Clinical Trial.
-
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.Drug Alcohol Depend. 2007 Oct 8;90(2-3):261-9. doi: 10.1016/j.drugalcdep.2007.04.006. Epub 2007 May 22. Drug Alcohol Depend. 2007. PMID: 17517480 Free PMC article. Clinical Trial.
-
The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Addiction. 2011 Aug;106(8):1460-73. doi: 10.1111/j.1360-0443.2011.03424.x. Epub 2011 May 3. Addiction. 2011. PMID: 21395892 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials